You are here

Article Text

Article menu

Download PDFPDF

Oral Presentations
WEDNESDAY, 12 JUNE 2019
SLE, Sjögren’s and APS – treatment
OP0045 ABATACEPT TREATMENT OF PATIENTS WITH EARLY ACTIVE PRIMARY SJÖGREN’S SYNDROME – A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED PHASE
Free
  1. Fred K.L. Spijkervet,
  2. Y.K. Onno Teng,
  3. E.J. Arends,
  4. III-STUDY (ASAP-III),
  5. Jolien F. van Nimwegen1,
  6. Greetje S. van Zuiden1,
  7. Suzanne Arends1,
  8. Esther Mossel1,
  9. Robin F. Wijnsma1,
  10. Alja J. Stel1,
  11. Konstantina Delli2,
  12. Bert van der Vegt3,
  13. Erlin A. Haacke1,3,
  14. Lisette Olie4,
  15. Leonie I. Los4,
  16. Janita Bulthuis-Kuiper1,
  17. Gwenny M. Verstappen1,
  18. Sarah A. Pringle1,
  19. Fred K.L. Spijkervet2,
  20. Frans G.M. Kroese2,
  21. Frans G.M. Kroese1,
  22. Arjan Vissink2,
  23. Hendrika Bootsma1
  1. 1University Medical Center Groningen, University of Groningen, Rheumatology and Clinical Immunology, Groningen, Netherlands
  2. 2University Medical Center Groningen, University of Groningen, Oral and Maxillofacial Surgery, Groningen, Netherlands
  3. 3University Medical Center Groningen, University of Groningen, Pathology and Medical Biology, Groningen, Netherlands
  4. 4University Medical Center Groningen, University of Groningen, Ophthalmology, Groningen, Netherlands

Abstract

Background Effective systemic treatment is not yet available for primary Sjögren syndrome (pSS). Abatacept (CTLA-4-Ig) targets the CD80/CD86:CD28 co-stimulatory pathway required for full T-cell activation and T-cell dependent activation of B-cells. IV abatacept was shown to be safe, well tolerated, and to decrease disease activity in an open-label study of 15 pSS patients.1

Objectives To assess the efficacy and safety of subcutaneous (SC) abatacept vs. placebo in patients with early active pSS.

Methods The Abatacept Sjögren Active Patients phase III (ASAP-III) study is a monocenter, investigator-initiated, double-blind, placebo-controlled trial (NCT02067910). ASAP-III included 80 adult patients with biopsy-proven pSS, fulfilling the AECG and ACR/EULAR criteria, with a disease duration of ≤7 years and moderate to high EULAR Sjögren’s syndrome disease activity score (ESSDAI ≥5). Patients were randomized in a 1:1 ratio to receive weekly SC abatacept (125 mg) or placebo for 24 weeks (figure 1). After the double-blind phase, all patients were treated with abatacept in a 24-week open label phase. Concomitant use of other DMARDs was not permitted, with the exception of a stable dose of prednisone (≤10mg). Rescue therapy with prednisone or cyclophosphamide was permitted after week 12. Participants visited our pSS tertiary referral center nine times, to be evaluated by a multidisciplinary team of rheumatologists, ophthalmologists, and oral and maxillofacial surgeons.

The primary endpoint is ESSDAI at 24 weeks. Secondary outcomes over 24 and 48 weeks include clinical, patient reported, functional, histological, laboratory, ultrasound, and microbiome parameters, and the occurrence of (serious) adverse events and treatment discontinuation.

Results Baseline characteristics of participants are shown in table 1. Database lock for the blinded stage is planned in March 2019. Subsequently, the first intention-to-treat analyses will be performed, focusing on the ESSDAI and EULAR Sjögren Syndrome Patient Reported Index (ESSPRI), quality of life (EQ-5D), unstimulated and stimulated whole salivary flow (UWS, SWS), Schirmer test, Ocular Staining Score (OSS), serological parameters (RF, IgG), and safety parameters.

Conclusion The ASAP-III trial was designed to assess the clinical efficacy and safety of SC abatacept in pSS patients with short disease duration and active disease. The 24-week results will be available during the EULAR congress 2019.

Figure 1
Figure 1

Design of the ASAPIII study.

Reference [1] Meiners, et al. Ann Rheum Dis2014;73:1393-6.

View this table:
Table 1:

Baseline characteristics of participants (n=80)

Disclosure of Interests Jolien F. van Nimwegen Speakers bureau: Bristol-Myers Squibb, Greetje S. van Zuiden Speakers bureau: Roche, Suzanne Arends Grant/research support from: Grant/research support from Pfizer, Esther Mossel: None declared, Robin F. Wijnsma: None declared, Alja J. Stel: None declared, Konstantina Delli: None declared, Bert van der Vegt: None declared, Erlin A. Haacke: None declared, Lisette Olie: None declared, Leonie I. Los: None declared, Janita Bulthuis-Kuiper: None declared, Gwenny M. Verstappen: None declared, Sarah A. Pringle: None declared, Fred K.L. Spijkervet: None declared, Frans G.M. Kroese Grant/research support from: Unrestricted grant from Bristol-Myers Squibb, Consultant for: Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, Roche, Janssen-Cilag, Arjan Vissink: None declared, Hendrika Bootsma Grant/research support from: Unrestricted grants from Bristol-Myers Squibb and Roche, Consultant for: Roche, Bristol-Myers Squibb, Novartis, Medimmune, Union Chimique Belge, Speakers bureau: Bristol-Myers Squibb, Novartis

https://doi.org/10.1136/annrheumdis-2019-eular.970

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.